NCT00895544已完成1 期
An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 231
- 试验地点
- 3
- 主要终点
- Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the booster vaccination defined as titer measured by microneutralization test >= 1:20.
研究概览
简要总结
The main objective of the study is to assess the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult population when administered according to a single prime-boost schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 59 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects will be eligible for participation in this study if they:
- •are 18 to 59 years of age, inclusive, on the day of screening
- •have an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry
- •are generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination
- •are physically and mentally capable of participating in the study and follow its procedures
- •agree to keep a daily record of symptoms for the duration of the study
- •if female of childbearing potential: have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study
排除标准
- •Subjects will be excluded from participation in this study if they:
- •have a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
- •are at high risk of contracting H5N1 influenza infection (e.g. poultry workers)
- •currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •have any inherited or acquired immunodeficiency
- •have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (> 800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
- •have a history of severe allergic reactions or anaphylaxis
- •have a rash, dermatological condition or tattoos which may interfere with injection site reaction rating
- •have received any blood products or immunoglobulins within 90 days prior to study entry
- •have donated blood or plasma within 30 days prior to study entry
- •have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study
- •have a functional or surgical asplenia
- •have a known or suspected problem with alcohol or drug abuse
- •were administered an investigational drug within 6 weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product
- •are a member of the team conducting this study or are in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study
- •if female: are pregnant or lactating
研究组 & 干预措施
1
Experimental
Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
干预措施: Influenza vaccine (whole virion, Vero cell derived) (Biological)
2
Experimental
Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
干预措施: Influenza vaccine (whole virion, Vero cell derived) (Biological)
结局指标
主要结局
Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the booster vaccination defined as titer measured by microneutralization test >= 1:20.
时间窗: 21 days
次要结局
- Number of subjects with antibody response associated with protection 21, 42, 180 and 360 days after the priming vaccination and 21 days after the booster vaccination(at the timepoints stated above)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A/H1N1 Immunogenicity and Safety in Infants, Children and AdolescentsPandemic InfluenzaInfluenzaNCT00976469Resilience Government Services, Inc.400
已完成
3 期
Japanese Pediatric H5N1 Vaccine StudyInfluenzaNCT01911754Resilience Government Services, Inc.60
已完成
3 期
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and OlderInfluenzaNCT01774032Resilience Government Services, Inc.91
已完成
2 期
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59Influenza A Virus, H5N1 SubtypeNCT03497845Biomedical Advanced Research and Development Authority720
进行中（未招募）
不适用
A phase II, open, study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine when administered as a booster dose to children aged 16-20 months, previously primed with GSK Biologicals’ combined DSSITGDPa-HBV-IPV/Hib vaccine, containing diphtheria toxoid from the Statens Serum Institute (SSI) of Denmark and tetanus toxoid from GSK Biologicals’ Kft [GD] or with GSK Biologicals licensed DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) in the primary vaccination study DTPa-HBV-IPV-116 (106786). - DTPa-HBV-IPV-120 BST:116Booster immunisation of healthy toddlers in the second year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b.EUCTR2007-005343-16-FIGlaxoSmithKline Biologicals450